Evotec at a Crossroads as AGM Nears and Technical Indicators Flash Warning

Evotec faces activist pressure for a break-up as stock trades below key moving averages. AGM votes on board and restructuring amid revenue decline and high volatility.

Evotec's shareholders head into Thursday's annual general meeting with no shortage of drama. An activist investor is pushing for a radical break-up of the company, yet the stock is trading below every major moving average — a technical picture that leaves little room for error. The shares recently changed hands at €4.93, though they dipped to €4.88 on the eve of the meeting, marking a third consecutive losing session. That puts them a mere 22% above the 52-week low of €4.02, a level tested in March and still very much in play.

The technical backdrop is unambiguously bearish. Evotec is trading beneath the 50-day simple moving average at €5.01, the 100-day SMA at €5.30, and the 200-day SMA at €5.63. As long as that remains the case, any bounce is likely to be a counter-trend rally rather than a genuine reversal. The 14-day relative strength index sits at 46.4 — squarely in neutral territory, offering no oversold signal that might attract dip-buyers. With annualised 30-day volatility of 45.6%, clear breakpoints become critical. A sustained move above €5.01 would be the first constructive sign, followed by a retake of €5.30. Only then would the technical outlook brighten meaningfully.

For the board, the immediate pressure is not just from the charts. Activist shareholder MAK Capital is demanding the separation of Just Evotec Biologics, a business many see as the crown jewel within the group. The proposal has split opinion among investors, and the AGM will provide a venue for debate. Management, however, is pursuing its own path via the "Horizon" restructuring programme, which calls for cutting the number of sites from more than a dozen to ten and achieving €75 million in annual savings by 2027. The goal is a return to profitability, though the first operational results under the new strategy were mixed at best.

First-quarter revenue fell nearly 22% to €156.6 million, while the loss per share widened to minus €0.69. For the full year, Evotec guides for revenue in a range of €700 million to €780 million, with adjusted EBITDA between zero and €40 million. Those numbers underscore the strain the company is under as it tries to trim costs without gutting the long-term potential of its biologics unit — the very asset MAK Capital wants to spin off.

The AGM agenda also includes elections for the supervisory board. Dieter Weinand and Wesley Wheeler are slated to join, and a performance share plan for 2026 is up for a vote. Meanwhile, the recent placement of convertible bonds has kept the question of capital structure front and centre. The combination of activist demands, restructuring execution, and a stock that has lost 31% over the past twelve months (and 11% year-to-date) creates a high-stakes atmosphere.

Evotec's situation is a reminder that even a modest distance from a 52-week low offers little comfort when the trend is against you. The next few days will show whether the AGM delivers the catalyst needed to challenge those overhead moving averages — or whether the bears remain in control.